drugset / Trial / NCT02806232

An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)

NCT02806232

Phase 2 Completed 444 enrolled Merck KGaA, Darmstadt, Germany
RandomizedParallel-groupOpen-labelTreatment

Summary

The Phase II study consisted of two parts, part 1 is open label, randomized, controlled and exploratory dose finding in children aged between 2 and 6 years infected with S. mansoni. Part 2 investigated efficacy and safety with the selected formulation and dosage in S. mansoni infected children aged between 3 months - 2 years.

Timeline

Start
2016-06-12
Primary completion
2018-10-30
Completion
2018-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Levo Praziquantel Unknown 30 mg/kg Oral
Subject Levo Praziquantel Unknown 45 mg/kg Oral
Subject Levo Praziquantel Unknown 50 mg/kg Oral
Subject Levo Praziquantel Unknown 60 mg/kg Oral
Subject Praziquantel Small molecule 20 mg/kg Oral
Subject Praziquantel Small molecule 40 mg/kg Oral
Subject Praziquantel Small molecule 60 mg/kg Oral